Alexandria For Pharmaceuticals & Chemical Industries Past Earnings Performance
Past criteria checks 3/6
Alexandria For Pharmaceuticals & Chemical Industries's earnings have been declining at an average annual rate of -0.03%, while the Pharmaceuticals industry saw earnings growing at 3.1% annually. Revenues have been growing at an average rate of 13.2% per year. Alexandria For Pharmaceuticals & Chemical Industries's return on equity is 21%, and it has net margins of 9.3%.
Key information
-0.03%
Earnings growth rate
1.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 9.8% |
| Revenue growth rate | 13.2% |
| Return on equity | 21.0% |
| Net Margin | 9.3% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Alexandria For Pharmaceuticals & Chemical Industries makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 1,628 | 151 | 33 | 0 |
| 30 Jun 23 | 1,484 | 126 | 84 | 0 |
| 30 Sep 22 | 1,154 | 123 | 78 | 0 |
| 30 Jun 22 | 1,100 | 117 | 76 | 0 |
| 31 Mar 22 | 1,063 | 89 | 83 | 0 |
| 31 Dec 21 | 1,108 | 95 | 87 | 0 |
| 30 Sep 21 | 1,095 | 101 | 88 | 0 |
| 30 Jun 21 | 1,104 | 117 | 94 | 0 |
| 31 Mar 21 | 1,116 | 144 | 91 | 0 |
| 31 Dec 20 | 1,074 | 164 | 87 | 0 |
| 30 Sep 20 | 1,073 | 177 | 91 | 0 |
| 30 Jun 20 | 1,025 | 170 | 86 | 0 |
| 31 Mar 20 | 964 | 143 | 83 | 0 |
| 31 Dec 19 | 906 | 126 | 79 | 0 |
| 30 Sep 19 | 871 | 120 | 71 | 0 |
| 30 Jun 19 | 829 | 113 | 67 | 0 |
| 31 Mar 19 | 781 | 117 | 65 | 0 |
| 31 Dec 18 | 776 | 119 | 61 | 0 |
| 30 Sep 18 | 746 | 112 | 59 | 0 |
| 30 Jun 18 | 704 | 118 | 57 | 0 |
| 31 Mar 18 | 682 | 124 | 82 | 0 |
| 31 Dec 17 | 633 | 127 | 72 | 0 |
| 30 Sep 17 | 558 | 107 | 60 | 0 |
| 30 Jun 17 | 511 | 91 | 50 | 0 |
| 31 Mar 17 | 508 | 97 | 45 | 0 |
| 31 Dec 16 | 457 | 74 | 13 | 0 |
| 30 Sep 16 | 433 | 77 | 13 | 0 |
| 30 Jun 16 | 419 | 72 | 13 | 0 |
| 31 Mar 16 | 399 | 60 | 43 | 0 |
| 31 Dec 15 | 394 | 65 | 43 | 0 |
| 30 Sep 15 | 388 | 62 | 43 | 0 |
| 30 Jun 15 | 377 | 59 | 43 | 0 |
| 31 Mar 15 | 368 | 56 | 11 | 0 |
| 31 Dec 14 | 352 | 53 | 11 | 0 |
| 30 Sep 14 | 329 | 49 | 11 | 0 |
| 30 Jun 14 | 308 | 48 | 10 | 0 |
| 31 Mar 14 | 307 | 48 | 10 | 0 |
| 31 Dec 13 | 301 | 46 | 9 | 0 |
| 30 Sep 13 | 296 | 47 | 9 | 0 |
| 30 Jun 13 | 289 | 48 | 9 | 0 |
Quality Earnings: AXPH has high quality earnings.
Growing Profit Margin: AXPH's current net profit margins (9.3%) are lower than last year (10.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AXPH's earnings have declined by 0.03% per year over the past 5 years.
Accelerating Growth: AXPH's earnings growth over the past year (22.4%) exceeds its 5-year average (-0.03% per year).
Earnings vs Industry: AXPH earnings growth over the past year (22.4%) did not outperform the Pharmaceuticals industry 27.9%.
Return on Equity
High ROE: AXPH's Return on Equity (21%) is considered high.